title: Donor single nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD.
abstract: The interactions between chemokines and their receptors may have an important role in initiating GVHD after allogeneic hematopoietic SCT (allo-HSCT). CCL25 and CCR9 are unique because they are exclusively expressed in epithelial cells and in Peyer's patches of the small intestine. We focused on rs12721497 (G926A), one of the non-synonymous single nucleotide polymorphisms (SNPs) in the CCR9 gene, and analyzed the SNP of donors in 167 consecutive patients who received allo-HSCT from an HLA-identical sibling donor. Genotypes were tested for associations with acute and chronic GVHD in each organ and transplant outcome. Multivariate analyses showed that the genotype 926AG was significantly associated with the incidence of acute stage > or =2 skin GVHD (hazard ratio: 3.2; 95% confidence interval (95% CI): 1.1-9.1; P=0.032) and chronic skin GVHD (hazard ratio: 4.1; 95% CI: 1.1-15; P=0.036), but not with GVHD in other organs or with relapse, non-relapse mortality or OS. To clarify the functional differences between genotypes, each SNP in retroviral vectors was transfected into Jurkat cells. In chemotaxis assays, the 926G transfectant showed greater response to CCL25 than the 926A transfectant. In conclusion, more active homing of CCR9-926AG T cells to Peyer's patches may produce changes in Ag presentation and result in increased incidence of skin GVHD.
authors.affiliation: Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Inamoto
authors.forename: M
authors.initials: M
authors.lastname: Murata
authors.forename: A
authors.initials: A
authors.lastname: Katsumi
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwatsuka
authors.forename: A
authors.initials: A
authors.lastname: Tsujimura
authors.forename: Y
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: M
authors.initials: M
authors.lastname: Onizuka
authors.forename: S
authors.initials: S
authors.lastname: Terakura
authors.forename: T
authors.initials: T
authors.lastname: Nishida
authors.forename: T
authors.initials: T
authors.lastname: Kanie
authors.forename: H
authors.initials: H
authors.lastname: Taji
authors.forename: H
authors.initials: H
authors.lastname: Iida
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: A
authors.initials: A
authors.lastname: Abe
authors.forename: H
authors.initials: H
authors.lastname: Kiyoi
authors.forename: T
authors.initials: T
authors.lastname: Matsushita
authors.forename: K
authors.initials: K
authors.lastname: Miyamura
authors.forename: Y
authors.initials: Y
authors.lastname: Kodera
authors.forename: T
authors.initials: T
authors.lastname: Naoe
mesh_terms: D000293:Adolescent; D000328:Adult; D002634:Chemotaxis, Leukocyte; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000235:genetics*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D019169:Jurkat Cells / Q000502:physiology; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D054388:Receptors, CCR / Q000235:genetics*; D012871:Skin Diseases / Q000453:epidemiology / Q000209:etiology; D014019:Tissue Donors; D016896:Treatment Outcome
chemical_list: C119309:CC chemokine receptor 9; D054388:Receptors, CCR